Danielle R Rios1, Jeffrey R Kaiser2. 1. Department of Pediatrics, Section of Neonatology, Baylor College of Medicine and Texas Children's Hospital, Houston, TX. Electronic address: drrios@texaschildrens.org. 2. Department of Pediatrics, Section of Neonatology, Baylor College of Medicine and Texas Children's Hospital, Houston, TX; Department of Obstetrics and Gynecology, Baylor College of Medicine and Texas Children's Hospital, Houston, TX.
Abstract
OBJECTIVE: To evaluate vasopressin vs dopamine as initial therapy in extremely low birth weight (ELBW) infants with hypotension during the first 24 hours of life. STUDY DESIGN:ELBW infants with hypertension ≤ 30 weeks' gestation and ≤ 24 hours old randomly received treatment withvasopressin or dopamine in a blinded fashion. Normotensive infants not receivingvasopressor support served as a comparison group. RESULTS:Twenty ELBW infants with hypertension receivedvasopressin (n = 10) or dopamine (n = 10), and 50 were enrolled for comparison. Mean gestational age was 25.6 ± 1.4 weeks and birth weight 705 ± 154 g. Response to vasopressin paralleled that of dopamine in time to adequate mean blood pressure (Kaplan-Meier curve, P = .986); 90% of infants in each treatment group responded with adequate blood pressure. The vasopressin group received fewer doses of surfactant (P < .05), had lower PaCO2 values (P < .05), and were not tachycardic (P < .001) during vasopressin administration, compared with the dopamine group. CONCLUSIONS:Vasopressin in ELBW infants as the initial agent for early hypotension appeared safe. This pilot study supports a larger randomized controlled trial of vasopressin vs dopamine therapy in ELBW infants with hypotension.
RCT Entities:
OBJECTIVE: To evaluate vasopressin vs dopamine as initial therapy in extremely low birth weight (ELBW) infants with hypotension during the first 24 hours of life. STUDY DESIGN: ELBW infants with hypertension ≤ 30 weeks' gestation and ≤ 24 hours old randomly received treatment with vasopressin or dopamine in a blinded fashion. Normotensive infants not receiving vasopressor support served as a comparison group. RESULTS: Twenty ELBW infants with hypertension received vasopressin (n = 10) or dopamine (n = 10), and 50 were enrolled for comparison. Mean gestational age was 25.6 ± 1.4 weeks and birth weight 705 ± 154 g. Response to vasopressin paralleled that of dopamine in time to adequate mean blood pressure (Kaplan-Meier curve, P = .986); 90% of infants in each treatment group responded with adequate blood pressure. The vasopressin group received fewer doses of surfactant (P < .05), had lower PaCO2 values (P < .05), and were not tachycardic (P < .001) during vasopressin administration, compared with the dopamine group. CONCLUSIONS:Vasopressin in ELBW infants as the initial agent for early hypotension appeared safe. This pilot study supports a larger randomized controlled trial of vasopressin vs dopamine therapy in ELBW infants with hypotension.
Authors: R P Dellinger; Mitchell M Levy; Andrew Rhodes; Djillali Annane; Herwig Gerlach; Steven M Opal; Jonathan E Sevransky; Charles L Sprung; Ivor S Douglas; Roman Jaeschke; Tiffany M Osborn; Mark E Nunnally; Sean R Townsend; Konrad Reinhart; Ruth M Kleinpell; Derek C Angus; Clifford S Deutschman; Flavia R Machado; Gordon D Rubenfeld; Steven Webb; Richard J Beale; Jean-Louis Vincent; Rui Moreno Journal: Intensive Care Med Date: 2013-01-30 Impact factor: 17.440
Authors: Tamanna Moore; Enid M Hennessy; Jonathan Myles; Samantha J Johnson; Elizabeth S Draper; Kate L Costeloe; Neil Marlow Journal: BMJ Date: 2012-12-04
Authors: Regan E Giesinger; Kiran More; Jodie Odame; Amish Jain; Robert P Jankov; Patrick J McNamara Journal: Pediatr Res Date: 2017-10-04 Impact factor: 3.756
Authors: Mengwei Ni; Jeffrey R Kaiser; Brady S Moffett; Christopher J Rhee; Jennifer Placencia; Kimberly L Dinh; Joseph L Hagan; Danielle R Rios Journal: J Pediatr Pharmacol Ther Date: 2017 Nov-Dec
Authors: Leeann R Pavlek; Brian K Rivera; Charles V Smith; Joanie Randle; Cory Hanlon; Kristi Small; Edward F Bell; Matthew A Rysavy; Sara Conroy; Carl H Backes Journal: J Pediatr Date: 2021-04-21 Impact factor: 6.314
Authors: Laura E Miller; Matthew M Laughon; Reese H Clark; Kanecia O Zimmerman; Christoph P Hornik; Samia Aleem; P Brian Smith; Rachel G Greenberg Journal: J Perinatol Date: 2021-03-23 Impact factor: 3.225
Authors: Abdulrahman Salim Alsaadi; Katelyn Sushko; Vivian Bui; John Van Den Anker; Abdul Razak; Samira Samiee-Zafarghandy Journal: BMJ Paediatr Open Date: 2021-06-09